Evaluating the effect of Ivermectin on covid 19 patients

INTERVENTION: Intervention 1: Intervention group: Patients in the main group will receive the drug of this study after treatment with routine drugs of the disease. Ivermectin tablet is 14 mg, so that the patient will receive one Ivermectin tablet every 12 hours for 3 time and then on the seventh day. Patient symptoms and laboratory data and CT scan will be reviewed. Intervention 2: Control group: Patients in the control group will receive placebo after treatment with routine medication, which is quite similar to ivermectin in that the patient will receive one placebo tablet every 12 hours for 3 time, and then on the seventh day the patient's symptoms and Laboratory data and CT scan will be reviewed. CONDITION: COVID 19. ; Corona virus infection, unspecified U07.1 PRIMARY OUTCOME: Duration of hospitalization. Timepoint: Time of dyscharge. Method of measurement: Patient file. Viral diagnostic test. Timepoint: The first day of the study. Method of measurement: Polymerase chain reaction. SECONDARY OUTCOME: C_reactive protein. Timepoint: The first day of the study and the end of the study (7th day). Method of measurement: Lab test. Cell blood count. Timepoint: The first day of the study and the end of the study (7th day). Method of measurement: Lab test. Cough. Timepoint: Daily. Method of measurement: Patients interview and patient file. CT scan. Timepoint: The first day of the study and the end of the study (7th day). Method of measurement: CT scan set. Dyspnea. Timepoint: Daily. Method of measurement: Patients interview and patient file. Fever. Timepoint: Daily. Method of measurement: Thermometer. Respiratory rate. Timepoint: Daily. Method of measurement: Patient file. INCLUSION CRITERIA: Age =18 years Laboratory polymerase chain reaction (PCR) confirmed infection with COVID19 Hospitalized Satisfaction to participate in the study Acceptance of non‐participation in another study before the 28th day of the study